[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356286-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356286-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","association-of-tigit-and-cd155-with-kras-nras-braf-pik3ca-and-akt-gene-mutations-msi-status-cytokine-profiles-in-colorectal-cancer","Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations - MSI Status - Cytokine Profiles in Colorectal Cancer","","TIGIT and its ligand CD155 (PVR) are emerging immune checkpoint molecules in colorectal cancer, yet their relationships with mutational subtypes and the tumor immune milieu remain insufficiently defined. Paired colorectal tumors and matched surgical margins were analyzed to quantify TIGIT and CD155 by ELISA, assess clinicopathological links, and evaluate MSI status plus KRAS/NRAS/BRAF/PIK3CA/AKT1 mutations. Both proteins were elevated in tumors versus margins and aligned with immune programs in transcriptomic validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/association-of-tigit-and-cd155-with-kras-nras-braf-pik3ca-and-akt-gene-mutations-msi-status-cytokine-profiles-in-colorectal-cancer/356286/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/association-of-tigit-and-cd155-with-kras-nras-braf-pik3ca-and-akt-gene-mutations-msi-status-cytokine-profiles-in-colorectal-cancer/356286.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do TIGIT and CD155 levels differ between tumor tissue and surgical margins?","Question",{"text":63,"@type":64},"Both TIGIT and CD155 are significantly higher in tumor tissue compared with matched surgical margins.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What associations were found between TIGIT or CD155 and MSI status or key gene mutations?",{"text":68,"@type":64},"TIGIT is higher in MSI than MSS tumors and in BRAF-mutant versus BRAF wild-type tumors, while CD155 shows no consistent MSI- or mutation-dependent differences.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cytokines and transcriptomic programs link TIGIT and CD155 to tumor immune activity?",{"text":72,"@type":64},"Cytokine profiling identified IFN-g as a shared positive associate of both TIGIT and CD155; CD155 additionally associates with TRAIL, IL-1Ra, M-CSF, and PDGF-bb. In TCGA-CRC validation, TIGIT-high tumors show enrichment of interferon/inflammatory programs, whereas CD155-high tumors show proliferation-related MYC/E2F/G2M signatures.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356286,1790145665,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Article  \nAssociation of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer  \nBłaej Ochman 1, *, Piotr Limanówka 1, Sylwia Mielcarska 1, Agnieszka Kula 2, Miriam Dawidowicz 2, Dorota Hudy 1, Monika Szrot 3, Jerzy Piecuch 3, Zenon Czuba 4, Dariusz Waniczek 2  \nand Elbieta ´Swi˛etochowska 1  \nAcademic Editor: Daniel Gabriel Pons  \nReceived: 15 December 2025  \nRevised: 13 January 2026  \nAccepted: 15 January 2026  \nPublished: 17 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana, 41-808 Zabrze, Poland; [s82955@365.sum.edu.pl](s82955@365.sum.edu.pl) (P.L.); [d201109@365.sum.edu.pl](d201109@365.sum.edu.pl) (S.M.); [dorota.hudy@sum.edu.pl](dorota.hudy@sum.edu.pl) (D.H.); [eswietochowska@sum.edu.pl](eswietochowska@sum.edu.pl) (E.´S .)  \n2 Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Katowice, Poland; [d201070@365.sum.edu.pl](d201070@365.sum.edu.pl) (A.K.); [d201069@365.sum.edu.pl](d201069@365.sum.edu.pl) (M.D.); [dwaniczek@sum.edu.pl](dwaniczek@sum.edu.pl) (D.W.)  \n3 Department of General and Bariatric Surgery and Emergency Medicine in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 10 Marii Curie-Skłodowskiej, 41-800 Zabrze, Poland; [mszrot@sum.edu.pl](mszrot@sum.edu.pl) (M.S.); [jpiecuch@sum.edu.pl](jpiecuch@sum.edu.pl) (J.P.)  \n4 Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana, 41-808 Zabrze, Poland; [zczuba@sum.edu.pl](zczuba@sum.edu.pl)  \n* Correspondence: [d201228@365.sum.edu.pl](d201228@365.sum.edu.pl)  \nAbstract  \nTIGIT and its ligand CD155 (PVR) are emerging immune checkpoints in colorectal cancer (CRC), but their associations with mutational subtypes and the tumor immune milieu remain unclear. We quantified TIGIT and CD155 proteins by ELISA in paired CRC tumors and matched surgical margins (n = 131) and evaluated associations with clinicopathological features, MSI status, and KRAS/NRAS/BRAF/PIK3CA/AKT1 mutations (n = 104) . Both TIGIT and CD155 were significantly elevated in tumor tissue versus margins (p \u003C 0.0001) and showed no association with TNM stage, clinical stage, grade, or tumor location. TIGIT levels were higher in MSI than MSS tumors and in BRAF-mutant compared to BRAF wild-type tumors, while CD155 expression showed no consistent MSI-or mutation-dependent differences. Cytokine profiling identified IFN-g as the only shared positive associate of TIGIT and CD155; CD155 additionally associated with TRAIL, IL-1Ra, M-CSF, and PDGF-bb. In external transcriptomic validation (TCGA-CRC), GSEA indicated enrichment of interferon/inflammatory programs in TIGIT-high tumors, while CD155-high tumors preferentially showed proliferation-related MYC/E2F/G2M signatures. Together, these findings support tumor-wide upregulation of the TIGIT/CD155 axis in CRC and suggest that TIGIT, more than CD155, tracks with MSI/BRAF-associated immune activation, providing a rationale for patient stratification in checkpoint-directed immunotherapy.  \nKeywords: colorectal neoplasms; TIGIT; CD155; PVR; microsatellite instability (MSI); tumor immune microenvironment; KRAS; NRAS; PIK3CA; BRAF  \n1. Introduction  \nTIGIT (T cell immunoreceptor with Ig and ITIM domains) and its ligand CD155 (PVR) function as immune checkpoint molecules [1] . TIGIT is an inhibitory receptor expressed on the surface of distinct immune cell subsets, mainly T cells, such as CD8+,  \nCD4+, and regulatory T cells (Tregs), and also Natural Killer (NK) cells [1–3] . TIGIT primarily interacts with four ligands, among which CD155 is considered the do","cbCaipHqif2NpjtA","https://ap.wps.com/l/cbCaipHqif2NpjtA","pdf",4190985,33,"English","# Introduction\n## TIGIT and CD155 biology in immune checkpoints\n## Colorectal cancer molecular context and immune microenvironment\n# Abstract\n## Protein elevation and clinical associations\n## Cytokine profiling links\n## Transcriptomic validation and pathway enrichment","[{\"question\":\"How do TIGIT and CD155 levels differ between tumor tissue and surgical margins?\",\"answer\":\"Both TIGIT and CD155 are significantly higher in tumor tissue compared with matched surgical margins.\"},{\"question\":\"What associations were found between TIGIT or CD155 and MSI status or key gene mutations?\",\"answer\":\"TIGIT is higher in MSI than MSS tumors and in BRAF-mutant versus BRAF wild-type tumors, while CD155 shows no consistent MSI- or mutation-dependent differences.\"},{\"question\":\"Which cytokines and transcriptomic programs link TIGIT and CD155 to tumor immune activity?\",\"answer\":\"Cytokine profiling identified IFN-g as a shared positive associate of both TIGIT and CD155; CD155 additionally associates with TRAIL, IL-1Ra, M-CSF, and PDGF-bb. In TCGA-CRC validation, TIGIT-high tumors show enrichment of interferon/inflammatory programs, whereas CD155-high tumors show proliferation-related MYC/E2F/G2M signatures.\"}]","Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations - MSI Status - Cytokine Profiles in Colorectal Cancer | PDF",1790124431,83,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7032a12693ee85d2073eab3201a0dce0.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0760d2a59b9eda5edbc1837c60699ec8.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17376005a7bc7e33aa695a5b5db3ca10.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ca3d0338ae90a35cdefce96003ffda3.webp",980,1385]